Form 8-K

8-K — ORAGENICS INC

Accession: 0001493152-26-040645

Filed: 2026-08-28

Period: 2026-08-26

CIK: 0001174940

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001174940

2026-08-26

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934.

Date

of Report: August 26, 2026

(Date

of earliest event reported)

Oragenics,

Inc.

(Exact

name of registrant as specified in its charter)

001-32188

59-3410522

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

Number)

9015

Town Center Parkway,

Suite

143

Lakewood

Ranch, Florida

34202

(Address

of principal executive offices)

(Zip

Code)

813-286-7900

(Registrant’s

telephone number, including area code)

(Former

Name or Former Address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

OGEN

NYSE

American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM

3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING.

August 26, 2026, Oragenics, Inc. (the “Company”) received notification (the “Notice”) from the

NYSE American LLC (the “NYSE American”) that the Company is no longer in compliance with NYSE American’s continued

listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth

in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii)

requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing

operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a listed company to have stockholders’

equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most

recent fiscal years. The Company reported stockholders’ equity of $3.7 million at June 30, 2026, and had net losses in its last

five fiscal years ended December 31, 2025. The Company is also not currently eligible for any exemption in Section 1003(a) of the Company

Guide from the stockholders’ equity requirements.

The

Notice further provides that the Company must submit a plan of compliance (the “Plan”) by September 25, 2026 addressing

how it intends to regain compliance with the continued listing standards by February 25, 2028. The Plan is required to include specific

milestones, quarterly financial projections and details related to any strategic initiatives the Company plans to complete.

The

Company has begun to prepare its Plan for submission to the NYSE American by the September 25, 2026 deadline. If the NYSE American accepts

the Company’s plan, the Company will be able to continue its listing during the Plan period and will be subject to continued periodic

review by the NYSE American staff. If the Plan is not timely submitted, or not accepted, or is accepted but the Company is not in compliance

with the continued listing standards by February 25, 2028 or if the Company does not make progress consistent with the Plan during the

Plan period, the Company will be subject to delisting procedures as set forth in the NYSE American Company Guide.

The

Company will endeavor to undertake a transaction or transactions in the future to achieve compliance with the NYSE American’s requirements.

However, there can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing

standards within the required timeframe.

The

Notice has no immediate impact on the listing of the Company’s shares of common stock, par value $0.001 per share (the “Common

Stock”), which will continue to be listed and traded on the NYSE American during this period, subject to the Company’s

compliance with the other listing requirements of the NYSE American. The Common Stock will continue to trade under the symbol “OGEN”,

but will have an added designation of “.BC” to indicate the status of the Common Stock as “below compliance”.

The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange

Commission.

the Common Stock ultimately were to be delisted for any reason, it could negatively impact the Company by (i) reducing the liquidity

and market price of the Company’s Common Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock,

which could negatively impact the Company’s ability to raise equity financing; and (iii) limiting the Company’s ability to

use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital

markets; and (iv) impairing the Company’s ability to provide equity incentives to its employees.

FORWARD

LOOKING STATEMENTS. This Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the U.S.

Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s ability to regain compliance with

NYSE American continued listing standards, the timing and outcomes of clinical trials, the Company’s regulatory strategy and anticipated

IND submission, and the sufficiency of capital to fund operations. These statements are based on management’s current expectations

and are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company’s

most recent Forms 10-K, 10-Q, and other filings with the SEC, available through EDGAR at www.sec.gov. The Company undertakes no obligation

to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required

by law.

ITEM

8.01 OTHER EVENTS.

August 28, 2026, in accordance with the NYSE American’s procedures, the Company issued a press release discussing the matters disclosed

in Item 3.01 above. A copy of the press release is included herewith as Exhibit 99.1, which is incorporated by reference into this Item

8.01.

ITEM

9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release Dated, August 28, 2026.

104

Cover

page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

SIGNATURES

accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,

thereunto duly authorized on this 28th day of August 2026.

ORAGENICS,

INC.

(Registrant)

BY:

/s/

Janet Huffman

Janet

Huffman

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Oragenics

Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

SARASOTA,

Fla.—August 28, 2026— Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted

therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory

pathway, and NYSE American continued listing status.

Clinical

& Regulatory Momentum Continues

Oragenics

continues to advance ONP-002, its lead intranasal candidate for mTBI (concussion), through its Phase IIa feasibility trial in Australia.

To date, the Company has dosed nine participants across its active trial sites.

● Three

Australian clinical sites now active: Alfred Health, Mackay, and Royal Adelaide Hospital

● Nine

participants dosed to date

● Continued

site-level enrollment support and monitoring underway across all active sites

U.S.

Regulatory Update

The

Company has received responses from the U.S. Food and Drug Administration (FDA) related to its Type B meeting request briefing package,

submitted in July 2026. Oragenics is currently reviewing these items and remains focused on its goal of submitting an Investigational

New Drug (IND) application by the end of 2026.

NYSE

American Listing Status

August 26, 2026, Oragenics received a deficiency letter from NYSE American LLC notifying the Company that it is not in compliance with

the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. Section 1003(a)(ii)

requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing

operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a listed company to have stockholders’

equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most

recent fiscal years.. This is the same continued listing standard the Company previously addressed and regained compliance with in October

2025.

Under

NYSE American rules, the Company has 45 days from receipt of the deficiency letter within which to submit a plan to regain compliance

with the continued listing standards. If the plan is accepted, the Company will continue its listing during a cure period, subject to

periodic review by NYSE American staff. While the Company intends to submit a compliance plan to NYSE American within the required timeframe

and will endeavor to undertake a transaction or transactions in the future to achieve compliance with the NYSE American’s requirements

and believes that with continued execution of its clinical and regulatory milestones, it will regain full compliance with continued listing

requirements, there can be no assurances in this regard. If the Plan is not timely submitted, or not accepted, or is accepted but the

Company is not in compliance with the continued listing standards by February 25, 2028 or if the Company does not make progress consistent

with the Plan during the Plan period, the Company will be subject to delisting procedures as set forth in the NYSE American Company Guide.

Looking

Ahead

Oragenics

remains focused on execution across its clinical, regulatory, and corporate objectives: continued Phase IIa enrollment and dosing in

Australia, advancing its U.S. IND submission, and building out its broader CNS pipeline. The Company believes its recent progress —

including a third active Australian site, nine participants dosed, and constructive engagement with the FDA — reflects continued

momentum toward its year-end goals.

“We’re

encouraged by the pace of enrollment in Australia and by the FDA’s engagement on our Type B package,” said Janet Huffman,

Chief Executive Officer of Oragenics.

About

Oragenics

is a clinical-stage biopharmaceutical company pioneering brain-targeted therapeutics through its proprietary intranasal delivery technology.

The Company’s lead candidate, ONP-002, is being developed as a potential first-in-class treatment for mTBI (concussion). Oragenics

is advancing ONP-002 through Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow. For more information,

visit www.oragenics.com.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

Reform Act of 1995, including statements regarding the Company’s ability to regain compliance with NYSE American continued listing

standards, the timing and outcomes of clinical trials, the Company’s regulatory strategy and anticipated IND submission, and the

sufficiency of capital to fund operations. These statements are based on management’s current expectations and are subject to risks

and uncertainties that could cause actual results to differ materially, including those described in the Company’s most recent

Forms 10-K, 10-Q, and other filings with the SEC, available through EDGAR at www.sec.gov. The Company undertakes no obligation to update

or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by

law.

Contacts

Investor

Relations: irth Communications - IR@oragenics.com.com

Media

Relations: irth Communications — IR@oragenics.com.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 26, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 26, 2026

Entity File Number

001-32188

Entity Registrant Name

Oragenics,

Inc.

Entity Central Index Key

0001174940

Entity Tax Identification Number

59-3410522

Entity Incorporation, State or Country Code

Entity Address, Address Line One

9015

Town Center Parkway

Entity Address, Address Line Two

Suite

143

Entity Address, City or Town

Lakewood

Ranch

Entity Address, State or Province

Entity Address, Postal Zip Code

34202

City Area Code

813

Local Phone Number

286-7900

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

OGEN

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration